A randomised phase III study on capecitabine, oxaliplatin and bevacizumab with or without cetuximab in first-line advanced colorectal cancer, the CAIRO2 study of the Dutch Colorectal Cancer Group (DCCG). An interim analysis of toxicity-Reference-Cited by-同舟云学术

A randomised phase III study on capecitabine, oxaliplatin and bevacizumab with or without cetuximab in first-line advanced colorectal cancer, the CAIRO2 study of the Dutch Colorectal Cancer Group (DCCG). An interim analysis of toxicity

Published:2008-04 Issue:4 Volume:19 Page:734-738
ISSN:0923-7534
Container-title:Annals of Oncology
language:en
Short-container-title:Annals of Oncology

Author:

Tol J.,Koopman M.,Rodenburg C.J.,Cats A.,Creemers G.J.,Schrama J.G.,Erdkamp F.L.G.,Vos A.H.,Mol L.,Antonini N.F.,Punt C.J.A.

Publisher

Elsevier BV

Subject

Oncology,Hematology

Link

http://academic.oup.com/annonc/article-pdf/19/4/734/584204/mdm607.pdf

Reference18 articles.

1. New options and old dilemmas in the treatment of patients with advanced colorectal cancer;Punt;Ann Oncol,2004

2. Sequential versus combination chemotherapy with capecitabine, irinotecan, and oxaliplatin in advanced colorectal cancer (CAIRO): a phase III randomised controlled trial;Koopman;Lancet,2007

3. Targeted therapy in advanced colorectal cancer, an update;Tol;Targeted Oncology,2007

4. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer;Cunningham;N Engl J Med,2004

5. Cetuximab for the treatment of colorectal cancer;Jonker;N Engl J Med,2007

Cited by 153 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Primary tumor resection for asymptomatic colorectal cancer with unresectable metastasis: the end of the dilemma;Annals of Oncology;2024-09

2. The contemporary management of peritoneal metastasis: A journey from the cold past of treatment futility to a warm present and a bright future;CA: A Cancer Journal for Clinicians;2022-08-15

3. The first Middle East and North Africa expert consensus recommendations for the management of advanced colorectal cancer;Future Oncology;2022-08

4. Serum-based measurements of stromal activation through ADAM12 associate with poor prognosis in colorectal cancer;BMC Cancer;2022-04-12

5. Randomized phase II study of SOX+B-mab versus SOX+C-mab in patients with previously untreated recurrent advanced colorectal cancer with wild-type KRAS (MCSGO-1107 study);BMC Cancer;2021-08-23